anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients take a single dose of Chiauranib capsules for the pharmacokinetic study,then off for 5 days before the first cycle begins. In the subsequent treatment cycles, Chiauranib capsules are given orally once daily, 28 days as a cycle.
PROBLEM TO BE SOLVED: To obtain the subject new compound comprising a specific pyridylethoxybenzylidene compound useful e.g. as a production intermediate for a thiazolidinedione derivative having hypoglycemic and hypolipidemic actions and effective e.g. as an agent for the treatment of diabetes, hyperlipemia, etc. SOLUTION: The objective compound is a new compound expressed by the formula I (R<1> is H or a lower alkyl; R<2> is O or a group of the formula II), e.g. 4-[2-(5-ethyl-2-pyridyl)ethoxy]benzaldehyde. It is useful e.g. as an industrially advantageous intermediate for a thiazolidinedione derivative having hypoglycemic and hypolipidemic actions and useful e.g. as an agent for the treatment of diabetes and hyperlipemia. The compound can be produced by adding an aqueous solution of sodium hydroxide to a methylene chloride solution containing a 2-pyridine ethanol derivative of the formula III, benzyltributylammonium chloride and p-toluenesulfonyl chloride, adding p- hydroxybenzaldehyde and sodium hydroxide to the mixture under stirring at room temperature and heating at 40-50 deg.C to effect the reaction of the components.
PROBLEM TO BE SOLVED: To obtain an external preparation having hair restoring action such as depilation-preventing effect or trichogenous effect and capable of using as hair tonic and a trichogenous agent by including 5-aminolevulinic acid (derivative) as an active ingredient. SOLUTION: This external preparation is obtained by including 5- aminolevulinic acid (derivative), preferably in an amount of >=0.001 wt.% and <=10.0 wt.%, more preferably >=0.01 wt.% and <=5.0 wt.% as an active ingredient. 5-Aminolevulinic acid is called as δ-aminolevulinic acid and is a sort of amino acid represented by the formula HOOC-(CH2 )2 (CO)-CH2 -NH2 . 5- Aminolevulinic acid is widely distributed in various kinds of organisms and usually biosynthesized from succinylCoA and glycine by 5-aminolevulinic acid synthetase. 5-Aminolevulinic acid is known as intermediate for biosynthesis of porphyrin. 5-Aminolevulinic acid is produced by chemical synthesis method, biological fermentation method or enzymatic method.
OBJECTIVE: To examine the clinicopathological features, immunohistochemical profiles, and differential diagnosis of sclerosing angiomatiod nodular transformation (SANT).
METHODS: Three cases of SANT of the spleen, diagnosed between 2014 and 2023 at the Affiliated Hospital of Zunyi Medical University, were analysed. Pathological features were assessed using haematoxylin and eosin staining, followed by immunohistochemistry with the EnVision system. Additionally, a review of relevant literature was conducted.
RESULTS: The study included one male and two female patients aged 40-55 years, with a median age of 47.5 years. All lesions were solitary, with tumour diameters ranging from 4 to 7.4 cm (mean 5.7 cm). Gross examination demonstrated that the masses were well-demarcated from the surrounding splenic tissue, with no evident capsule. The cut surfaces of the masses exhibited irregular, porcelain-white nodules that were tough in consistency, with some areas intermingling with splenic tissue. Microscopic examination revealed round or circular nodules comprising multiple slit-like or sinusoidal capillaries, separated by concentric collagen fibres. The nodules exhibited chronic inflammatory cell infiltration, calcification, haemosiderin deposition, and fibrous connective tissue with hyaline or mucoid changes. Immunohistochemical analysis demonstrated differential expression of markers, including cluster of differentiation (CD) 34, CD31, and CD8, within the sinusoidal nodule areas. Periodic acid-Schiff staining was positive for perinodular collagen deposits, while reticulin staining highlighted nodule profiles and intranodular vessels. None of the patients experienced postoperative recurrence or metastasis, and one patient was on aspirin for thrombocytosis.
CONCLUSION: SANT of the spleen is generally considered a rare, benign lesion with angioma-like characteristics. It exhibits exhibiting distinctive histomorphological features within the red pulp. Understanding the differential diagnosis is crucial to prevent missed or incorrect diagnoses.
PURPOSE: Isothiazole derivatives, processes for preparing the same, and pharmaceutical compositions containing the same are provided. The isothiazole derivatives have improved fever-removing, pain-alleviating and anti-inflammatory activities and improves adverse side-effects of conventional non-steroidal anti-inflammatory agents. CONSTITUTION: Isothiazole derivatives represented by the formula(1) or non-toxic salts thereof are provided, wherein R1 is hydrogen, alkoxy or halogen; and R2 is methyl or amino. A method for preparing isothiazole derivatives of the formula(1a) comprises reacting a compound of the formula(7) with ammonia water. A method for preparing isothiazole derivatives of the formula(1b) comprises reacting a compound of the formula(7) with hydrazine and iodomethyl. A method for preparing isothiazole derivatives of the formula(1c) comprises reacting a compound of the formula(12) with P2S5 and 2,3,5,6-tetrachloro-1,4-benzoquinone.
Aim of the work To compare the quality of recovery (ObsQOR-11) in patients undergoing cesarean sections receiving dexmedetomedine either intrathecally or in the tap block in comparison to patients receiving conventional spinal anesthesia and tap block.

Statistical Analysis I. Sample size In a pilot study on 5 parturient who had undergone elective cesarean section under spinal anesthesia followed by TAP block with bupivacaine alone, the mean ObsQoR-11 at 24 hours was 65±9. In a single factor ANOVA study, sample size of 126 from the 3 groups is needed to detect a difference of at least 10 using the Tukey-Kramer (Pairwise) multiple comparison with study power of 83% and alpha error of 0.05. The common standard deviation within a group is assumed to be 9. The number of envelopes will be increased to 141 (47 per group) to compensate of possible 10% dropout. The sample size was calculated using PASS 15 Power Analysis and Sample Size Software (2017). NCSS, LLC. Kaysville, Utah, USA, ncss.com/software/pass.

II. Statistical analysis Data will be coded and entered using the statistical package SPSS (statistical package for the social science) version 22. Data will be summarized using mean, standard deviation, median, minimum and maximum in quantitative data and using frequency (count) and relative frequency(percentage)for categorical data. Comparisons between quantitative variables will be done using the non parametric Mann-Whitney test. For comparing categorical data, Chi square (x2 ) test will be performed. Exact test will be used instead when the expected frequency is less than 5. P-value less than 0.05 will be considered as statistically significant.
At the baseline/randomization visit, a QOL (Medical Outcomes Study Short Form-36) and lower urinary tract symptoms (LUTS) score assessment will be completed; urine and serum will be collected for measurement of diagnostic markers; plasma will be collected for measurement of baseline catechin levels; serum will be collected for banking; and diet recall forms will be collected. Participants will be equally randomized to blinded treatment with either Polyphenon E 200 mg EGCG bid or matching placebo, and an initial supply of study drug will be dispensed. All participants will also be provided with a standard multivitamin/mineral supplement to assure consistent, appropriate nutrient intake among study participants. The planned intervention period is 12 months; participants will return for monthly clinic visits during the intervention period. At each monthly clinic visit, blood will be drawn for repeat hepatic function panel, lactate dehydrogenase (LDH) and prothrombin time/partial thromboplastin time (PT/PTT), and participants will be interviewed to review and capture information from study agent intake log (pill count), assess signs and symptoms and concomitant medications; additional study medication will be dispensed as needed. After 3 and 6 months of intervention, blood will be drawn for serum chemistry and hematology, and LUTS and QOL assessments will be performed. In addition, at the 6 month visit, two-day diet recall forms will be collected, blood will be drawn for plasma catechin measurements and serum banking, serum and urine will be collected for diagnostic marker measurement, and repeat digital rectal exam (DRE) and prostate specific antigen (PSA) will be performed. If there is a palpable prostate nodule or confirmed PSA increase (\>0.75 ng/ml) at 6 months, a repeat biopsy will be performed. If the 6-month biopsy shows evidence of disease progression, participants will stop intervention and proceed to the post-intervention assessment; otherwise, intervention will continue through month 12. At the end of intervention (maximum of 12 months), a repeat prostate biopsy will be performed for post-intervention endpoint measurements. In addition, the physical exam and DRE, LUTS and QOL will be repeated, and 2-day diet recall forms will be collected. Blood will be drawn for serum chemistry and hematology, PSA, hepatic function panel, LDH, PT/PTT; serum and urine will be collected for diagnostic marker measurement; plasma will be collected for catechin measurements; and serum will be collected for banking. Participants will be interviewed to review and capture information from study agent intake log (pill count), assess signs and symptoms and concomitant medications.
This will be a controlled, randomised study, to be performed in 15-20 pancreas transplantation centers throughout Europe. Patients will be randomised into one of two treatment groups. Group 1 will receive Tacrolimus and Mycophenolate Mofetil (= best group in EuroSPK001 trial). Group 2 will receive Tacrolimus and Sirolimus. Both groups will receive in association short-term corticosteroids and polyclonal antibody preparation. Patients will be randomly assigned to one of the 2 treatment groups in a 1:1 ratio before transplantation. The study will last 3 years, with a first interim analysis of the data at 6 months and a complete analysis at 1 year.
The invasive capacity of lung adenocarcinoma (LUAD) is an important factor influencing patients' metastatic status and survival outcomes. However, there is still a lack of suitable biomarkers to evaluate tumor invasiveness. LUAD molecular subtypes were identified by unsupervised consistent clustering of LUAD. The differences in prognosis, tumor microenvironment (TME), and mutation were assessed among different subtypes. After that, the invasion-related gene score (IRGS) was constructed by genetic differential analysis, WGCNA analysis, and LASSO analysis, then we evaluated the relationship between IRGS and invasive characteristics, TME, and prognosis. The predictive ability of the IRGS was verified by in vitro experiments. Next, the "oncoPredict" R package and CMap were used to assess the potential value of IRGS in drug therapy. The results showed that LUAD was clustered into two molecular subtypes. And the C1 subtype exhibited a worse prognosis, higher stemness enrichment activity, less immune infiltration, and higher mutation frequency. Subsequently, IRGS developed based on molecular subtypes demonstrated a strong association with malignant characteristics such as invasive features, higher stemness scores, less immune infiltration, and worse survival. In vitro experiments showed that the higher IRGS LUAD cell had a stronger invasive capacity than the lower IRGS LUAD cell. Predictive analysis based on the "oncoPredict" R package showed that the high IRGS group was more sensitive to docetaxel, erlotinib, paclitaxel, and gefitinib. Among them, in vitro experiments verified the greater killing effect of paclitaxel on high IRGS cell lines. In addition, CMap showed that purvalanol-a, angiogenesis-inhibitor, and masitinib have potential therapeutic effects in the high IRGS group. In summary we identified and analyzed the molecular subtypes associated with the invasiveness of LUAD and developed IRGS that can efficiently predict the prognosis and invasive ability of the tumor. IRGS may be able to facilitate the precision treatment of LUAD to some extent.
PROBLEM TO BE SOLVED: To provide a process whereby a starch material which highly contains dietary fibers highly safe and having small particle sizes and smooth touch and which can be used in the fields of food and drink, medicines, etc., can be produced in a large amt. from starch industrially produced at a low cost. SOLUTION: A starch material highly contg. dietary fibers is obtd. by charging starch contg. 30wt.% or higher amylose into a pressure container equipped with both a depressurizing line and a pressurized steam line, depressurizing the container, and then repeating, pref. several times, the operation of pressurizing and heating the starch in the container pref. at 100-140 deg.C for 10-180min by introducing steam. A high-amylose corn starch and/or its deriv. or a mixture comprising 99-40wt.% high-amylose corn starch and/or its deriv. and 1-60wt.% starch contg. less than 30wt.% amylose is used as the starch contg. 30wt.% or higher amylose.
At Visit 1, single dose 1 drop of EXP039 1% is adminstered, followed by washout period of 1-10 days. Subsequently, subjects will crossover to single dose 1 drop saline at Visit 2.
The invention provides a polymer carbon nitride@Hittorf red phosphorus heterostructure and application thereof in preparation of a drug for targeted treatment of renal clear cell carcinoma, and belongs to the technical field of nano-drugs. The invention designs a near infrared light response Hittorf red phosphorus (HP) modified polymer carbon nitride heterostructure (PCN@HP) based on a simple Chemical Vapor Deposition (CVD) method. Experimental studies have found that HP nanorods grown vertically on PCN exhibit broad and strong light absorption in the near infrared range. In vitro and in vivo experiments prove that under the irradiation of near infrared light, the tumor inhibition rate reaches 100 percent when the concentration of the suspension is 100 mug/mL. Notably, the complex has no damage to normal tissues and cells, but has a significant targeted inhibition effect on deep ccRCC cells in vivo. In addition, the composite material has good biocompatibility and self-luminous effect, can be completely metabolized in 48 hours in vivo, is a nanoparticle with imaging and PDT/PTT cooperative treatment, and can be used for efficient tumor nanotherapy.
This study will investigate the utility of regimented sleep and lights in depressed subjects. Based on current timing of sleep, desired sleep time and responses to the Morningness-Eveningness Questionnaire, each subject who remains significantly depressed at their randomization (usually 2nd) visit, will be randomly assigned to one of two regimented sleep and light use protocols. On the night beginning their assigned regimented protocol, each subject will wear amber goggles for five hours and collect half hourly saliva samples for four hours. Each morning they will sit in front of a light box wearing goggles. During the first week following the start of the regimented protocol, they will complete self-report forms and have a telephone interview to document their depressive symptoms. They will have weekly in person interviews for six weeks and evaluations by an independent evaluator in person or by telephone at randomization, 2 and 6 weeks. Prior to their Week 2 Visit, they will wear the goggles for the four hours prior to their assigned bedtime and for the three hours prior to their assigned bedtime, they will collect half hourly saliva samples. At their Week 6 interview, they and their doctor will determine whether they have improved sufficiently or not. Their doctor will discuss with them whether it makes sense for them to continue the same regimented sleep/light schedule, make a change to it or switch to or add additional treatment, such as antidepressant medication. They will then be followed with study ratings monthly for six months, during which treatment is unrestricted; that is, the doctor and patient can determine what the treatment during this time will be. Following the six months follow-up, a referral will be made if appropriate.

All saliva samples will be analyzed for melatonin concentration.
Adalimumab-ryvk injection is supplied as a preservative-free, sterile, clear and colorless solution for subcutaneous administration. The following packaging configurations are available. 

  * Adalimumab-ryvk Autoinjector Carton - 40 mg/0.4 mL (Two Count)



Adalimumab-ryvk is supplied in a carton containing two alcohol preps and two dose trays. Each dose tray consists of a single-dose autoinjector, containing a 1 mL prefilled glass syringe with a fixed 29-gauge (1/2 inch) needle, providing 40 mg/0.4 mL of Adalimumab-ryvk. The Adalimumab-ryvk autoinjector is not made with natural rubber latex. The NDC number is NDC 82009-156-22.

  * Adalimumab-ryvk Prefilled Syringe Carton - 40 mg/0.4 mL (Two Count)



Adalimumab-ryvk is supplied in a carton containing two alcohol preps and two dose trays. Each dose tray consists of a single-dose, 1 mL prefilled glass syringe with a fixed thin wall, 1/2 inch needle and fitted with a plunger rod, finger grip and a rigid needle cover, providing 40 mg/0.4 mL of Adalimumab-ryvk. The gray needle cover is not made with natural rubber latex. The NDC number is NDC 82009-158-22. 

Storage and Stability

Do not use beyond the expiration date on the container. Adalimumab-ryvk must be refrigerated at 36°F to 46°F (2°C to 8°C). DO NOT FREEZE. Do not use if frozen even if it has been thawed.

Store in original carton until time of administration to protect from light.

If needed, for example when traveling, Adalimumab-ryvk may be stored at room temperature up to a maximum of 77°F (25°C) for a period of up to 30 days, with protection from light. Adalimumab-ryvk should be discarded if not used within the 30-day period. Record the date when Adalimumab-ryvk is first removed from the refrigerator in the spaces provided on the carton and dose tray.

Do not store Adalimumab-ryvk in extreme heat or cold.
Genetic mutations have closely linked to the pathogenesis and prognostication of myeloid cancers (including acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms). In recent years, a number of novel therapeutic agents targeting various genetic mutations have been developed. For instance, patients with FLT3-ITD and IDH2 mutations have been shown to derive benefits from midostaurin and enasidenib, respectively. Furthermore, the TP53-mutated patients once categorized in the very high risk group, have been found to respond favorably to the hypomethylating agent, decitabine. Detecting a wide array of cancer mutations nowadays by the traditional Sanger method has become not only time-consuming but also not as cost-effective. With the advent of next generation sequencing (NGS), we now are able to detect a panel gene mutations more rapidly, accurately, and economically.

In this study, the investigators will screen and analyze myeloid-associated gene mutations in participants with myeloid cancers, with an in-house designed targeted NGS panel. The total nucleic acid from patients' blood or bone marrow specimens will be extracted, and then subjected to the library preparation procedure based on multiplex PCR amplification. Sequencing will be performed on Illumina MiSeq sequencer, and the results will be analyzed using our in-house developed bioinformatic workflow. Briefly, the sequenced reads will be aligned to human reference genome hg19 with BWA-mem, and somatic mutations called with Mutect2. The variants will be annotated via SnpEff with RefSeq, dbSNP, 1000 Genome Project, COSMIC and ClinVar databases. The investigators aim to build up the mutational landscapes of the above mentioned myeloid cancers, and investigate how these mutations are linked to clinical outcome.
Within 12-72 hours of birth, infants will receive 80 mg myo-inositol 5% Injection per kilogram per day, administered in divided doses every 12 hours (40 mg/kg/dose). Study drug will be administered daily and continued until the earliest of 34 completed weeks PMA, 10 weeks (70 days) chronologic age, or the time of discharge. myo-Inositol 5% Injection will be administered IV until enteral feedings are established, at which time the same dose and formulation will be administered enterally every 12 hours.
OBJECTIVE: The study was conducted to evaluate the safety and efficacy of mild internal jugular (IJV) compression via an FDA approved compression collar for symptomatic treatment of venous pulsatile tinnitus.
METHODS: This is a prospective study that recruited 20 adult patients with venous pulsatile tinnitus. Participants completed the Tinnitus Handicap Inventory (THI), were fitted with the collar, and rated symptom intensity on a 10-point tinnitus intensity scale before and during collar use. Once weekly for 4 weeks, they answered a survey quantifying days used, average tinnitus intensity before and after wearing the collar each day of use, and any safety concerns. Lastly, they completed an exit interview. The primary outcome was symptomatic relief, with secondary outcomes of safety, effect of treatment setting, effect of time, and quality of life assessed via nonparametric testing.
RESULTS: 18 participants completed the study, and 276 paired daily before use/during use intensity scores were submitted. The median symptom intensity without the collar was 6 (IQR 4, 7), whereas with the collar it was 3 (IQR 2, 5), for a median symptomatic relief of 50%. The collar had a significant effect in reducing symptom intensity (p < 0.0001) and burden of illness via the THI (p < 0.0001). There was no effect of setting, frequency, or time on symptomatic relief with the collar. There were no adverse safety events reported aside from minor discomfort upon initial application.
CONCLUSIONS: Venous compression collars offer acute symptom relief for patients with venous pulsatile tinnitus. Further study is needed to assess safety and efficacy of longitudinal use.
LEVEL OF EVIDENCE: 4 Laryngoscope, 134:3342-3348, 2024.
Tumor-associated macrophages (TAMs) undergo metabolic reprogramming, encompassing glucose, amino acid, fatty acid metabolism, tricarboxylic acid (TCA) cycle, purine metabolism, and autophagy, within the tumor microenvironment (TME). The metabolic interdependencies between TAMs and tumor cells critically influence macrophage recruitment, differentiation, M2 polarization, and secretion of epithelial-mesenchymal transition (EMT)-related factors, thereby activating intratumoral EMT pathways and enhancing tumor cell invasion and metastasis. Tumor cell metabolic alterations, including hypoxia, metabolite secretion, aerobic metabolism, and autophagy, affect the TME's metabolic landscape, driving macrophage recruitment, differentiation, M2 polarization, and metabolic reprogramming, ultimately facilitating EMT, invasion, and metastasis. Additionally, macrophages can induce tumor cell EMT by reprogramming their aerobic glycolysis. Recent experimental and clinical studies have focused on the metabolic interactions between macrophages and tumor cells to control metastasis and inhibit tumor progression. This review highlights the regulatory role of TAM-tumor cell metabolic codependencies in EMT, offering valuable insights for TAM-targeted therapies in highly metastatic tumors. Modulating the metabolic interplay between tumors and TAMs represents a promising therapeutic strategy for treating patients with metastatic cancers.
Similar to Arm 1, with Multiple Traffic Light labels displayed on all products FOP. A 60-second introductory video briefly explaining the MTL scheme will be shown before each shop in this Arm.